To study interactions between insulin-like growth factor-II (IGF-II) and growth hormone (GH) in vivo, we crossed hemizygous transgenic mice carrying phosphoenolpyruvate carboxykinase (PEPCK)-IGF-II fusion genes with hemizygous PEPCK-bovine GH (bGH) transgenic mice. Offspring harbouring both transgenes (IB), the IGF-II transgene (I) or the bGH transgene (B), and non-transgenic littermates (C) were obtained. Blood samples were taken before (end of week 12) and after (end of week 14) the mice had received a diet high in protein and low in carbohydrates to stimulate PEPCK promoter-controlled transgene expression. Mean serum GH concentrations of both B and IB mice corresponded to 900 ng/ml and increased more than twofold (P < 0.001) after 1 week of the high-protein diet. GH concentrations in controls and I mice were less than 20 ng/ml. Serum IGF-II concentrations in I and IB mice were three-to fourfold higher than those in C and B mice. Whereas IGF-II concentrations were not changed by the high-protein diet in the last two groups, serum IGF-II increased significantly in I (P < 0.001) and IB mice (P < 0.05). This increase was significantly (P < 0.05) less pronounced in IB than in I mice. Circulating IGF-I concentrations were about twofold (P < 0.001) higher in B and IB than in C and I mice, and showed a tendency to be lower in I than in C and in IB than in B mice when animals were maintained on the standard diet. The high-protein diet did not change circulating IGF-I concentrations in controls and B mice, but resulted in a significant reduction of serum IGF-I concentrations in I (P < 0.05) and IB mice (P < 0.001). Consequently, after PEPCK-IGF-II transgene expression was stimulated, serum IGF-I concentrations were significantly (P < 0.05) lower in I than in C and in IB than in B mice. Serum IGF-binding protein (IGFBP)-2 concentrations were significantly (P < 0:05) higher in I mice than in all other groups when mice were maintained on the standard diet, with a tendency to reduced IGFBP-2 concentrations in B mice. After the high-protein diet, serum IGFBP-2 concentrations did not change in C and I mice, but increased by two-to threefold in B and IB mice (P < 0:001). Serum IGFBP-3 concentrations tended to be greater in B and IB than in C and I mice, but these differences were mostly not significant. IGFBP-4 concentrations were significantly (P < 0:001) increased by GH overproduction in B and IB mice. Our data suggest that the reduction in circulating IGF-I concentrations by increased IGF-II is most probably due to the limited serum IGF binding capacity and the short half-life of free IGFs, rather than to a reduction in GH-dependent IGF-I production. Effects of GH overproduction on serum IGFBP-2 concentrations depend on dietary factors and may be both inhibitory and stimulatory.
Introduction
An important role of insulin-like growth factor-II (IGF-II) as a main regulator of fetal and placental growth has been demonstrated by reduced prenatal growth of mice lacking a functional IGF-II allele (1) (2) (3) . Conversely, fetal overabundance of IGF-II as a consequence of targeted inactivation of the IGF-II/cation-independent mannose 6-phosphate receptor (Igf2/Mpr) gene in mice caused fetal overgrowth and perinatal death (4, 5) . Although the actions of IGF-II in prenatal growth and differentiation are becoming increasingly clear, the role of this peptide for postnatal growth physiology remains puzzling (for review, see Ref. 6) .
To facilitate the study of this problem, various transgenic mouse models have been created that overproduce human (7) (8) (9) or murine IGF-II (10) . These models exhibited different alterations in postnatal growth. Mice carrying major urinary protein (MUP)-human IGF-II transgenes displayed significantly reduced body weight, lean body mass and fat mass (7) . Transgenic mice expressing the coding exons of the mouse IGF-II gene under the control of a bovine keratin (BKVI) promoter were also leaner than controls, but exhibited slightly increased body weight at 2 and 3 months of age, overgrowth of the skin and increased weights of the appendix, colon and uterus (10) . The most prominent finding in transgenic mice expressing human IGF-II minigenes driven by the H-2K b promoter-enhancer was increased growth of the thymus (9) . Our studies on transgenic mice expressing a human IGF-II complementary DNA under the control of phosphoenolpyruvate carboxykinase (PEPCK) regulatory sequences suggested that increased circulating IGF-II in the postnatal period does not play a significant part in body and skeletal growth (8, 11) . These animals showed only a subtle time-specific increase in the weights of kidneys, testes and adrenal glands. However, increased IGF-II caused a number of changes in other components of the IGF system, such as a significant increase in circulating IGF-binding protein-2 (IGFBP-2) and a decrease in serum IGF-I concentrations, which might -at least in part -be responsible for the lack of major growth effects in PEPCK-IGF-II transgenic mice.
We therefore studied effects of increased IGF-II in the presence of simultaneously increased IGF-I concentrations by crossing hemizygous PEPCK-IGF-II transgenic mice with hemizygous PEPCK-bovine growth hormone (bGH) transgenic mice. Four genetic groups were obtained that carryed both transgenes (IB), the PEPCK-IGF-II (I) or the PEPCK-bGH transgene (B), and non-transgenic controls (C). IGF-II overproduction did not significantly affect overall body growth and the growth of most internal organs, but showed a tendency to increase the weights of kidneys, adrenal glands and pancreas, both in the absence and in the presence of the bGH transgene. GH and IGF-II were additive in stimulating the growth of uterus and spleen in female mice. Analysis of organ weight/body weight ratios demonstrated significant effects of IGF-II overproduction on the relative growth of kidneys and adrenal glands (12) .
The present study investigated the relationship of serum concentrations of IGFs-I and -II in these mice, and the effects on circulating IGFBPs, which represent important modulators of biological actions of IGFs (for review, see Ref. 13 ). Specifically, this approach aimed at elucidating the mechanism of the decrease in serum IGF-I concentrations that is a consistent feature of in vivo studies involving administration of IGF-II to pituitary-sufficient animals (14) or transplantation of IGF-II-secreting tumours to nude rodents (15) .
Materials and methods

Generation of transgenic mice and animal husbandry
Transgenic mice carrying PEPCK-IGF-II gene constructs including 550 bp of the PEPCK promoter, 120 bp rat insulin II intron A sequences, the human IGF-II coding region, and 420 bp of the terminating sequences of the human GH gene were produced by pronuclear DNA microinjection as described previously (8) . Expression of the transgene was detected in liver, kidneys and several parts of the gastrointestinal tract.
PEPCK-bGH transgenic mice were originally generated (16) and kindly provided by Dr T E Wagner, Edison Biotechnology Center, Ohio University, Athens, Ohio, USA. The presence of the transgene, which is expressed in liver and kidneys, was shown by polymerase chain reaction as described elsewhere (17) .
Hemizygous PEPCK-IGF-II transgenic females were mated with hemizygous PEPCK-bGH transgenic males to generate four different genetic groups of offspring: animals harbouring both transgenes (IB), the PEPCK-IGF-II transgene (I) or the PEPCK-bGH transgene (B), and non-transgenic controls (C). After weaning at 3 weeks of age, the animals were fed a standard rodent diet (Altromin 1324; Altromin, Lage, Germany: 185.5 g protein, 535.6 g disaccharide, 38 .0 g fat, 590 kJ convertible energy per kg). During week 14, a diet high in protein and low in carbohydrates (Altromin 1001; 547.2 g protein, 6.7 g disaccharide, 111.6 g fat, 753 kJ convertible energy per kg) was fed to stimulate PEPCK promoter-controlled transgene expression. All animals were kept under conventional (non-barrier) conditions; food and tap water were available ad libitum.
Quantification of circulating IGFs-I and -II, IGFBP-2, GH and insulin concentrations
Two blood samples (end of week 12, end of week 14; between 0900 and 1100 h) were obtained from each mouse by bleeding from the retro-orbital sinus, with the animal under ether anesthesia, and centrifuged (2 × 10 min; 15 000 × g) to obtain serum.
Circulating IGFs-I and -II were measured by RIA (18, 19) . For IGF-II determination, serum samples were diluted 1 : 50 in acidic phosphate buffer (10 mmol/l pH 2.1). Subsequently, IGFBPs were blocked with an excess of recombinant human IGF-I (25 ng/tube). This method has been studied systematically, and it has been shown that IGF-II is measured correctly with this third generation assay (20) . The assay detects both human and mouse IGF-II, as shown by substantial levels of immunoreactivity in serum samples from nontransgenic control mice (8, 11) . To determine whether PEPCK-IGF-II transgenic mice secrete the mature form of IGF-II, a 200 ml serum sample was acidified with 15 ml of 5 mol/l phosphoric acid to achieve a pH of 2.1 and fractionated on a gel filtration column using a fluidphase liquid chromatography system. The Superdex 75 column (15 mm × 30 cm) was equilibrated in 10 mmol/l sodium dihydrogenphosphate containing 0.1% Tween 20 pH 2.1, and calibrated with molecular weight markers from 2000 kDa to 70 Da (2000 kDa dextran blue; 45 kDa ovalbumin; 13.7 kDa ribonuclease A; 6.5 kDa aprotinin; 0.07 kDa sodium azide) at a linear flow rate of 0.2 ml/min. The resulting peaks were detected by measuring the u.v. absorption at 280 nm. The serum sample was chromatographed and fractions of 300 ml were collected in an ice bath. The fractions were frozen at ¹20 ЊC until required for analysis for IGF-II immunoreactivity by RIA.
For IGF-I measurement, serum samples were diluted 1 : 150 with a 10 mmol/l phosphate buffer (pH 2.8).
Upon re-neutralization with assay buffer, an excess of recombinant IGF-II (25 ng/tube; Mediagnost, Tü bingen, Germany) was added simultaneously to block IGFBP binding sites. Serum IGFBP-2 was measured by RIA in samples diluted 1 : 30 with assay buffer as described previously (8, 21) .
Circulating GH was determined by an ELISA for bGH (22) . With this assay, GH concentrations in serum samples from controls were less than 20 ng/ml.
Serum insulin concentrations were measured using a commercially available RIA kit (INSULIN CT, CIS Bio International, Gif-sur-Yvette, France) for human insulin with 89.5% cross-reactivity for rat insulin (8) .
Ligand blot analysis of serum IGFBPs
Ligand blot analysis of serum IGFBPs was performed according to the method of Hossenlopp et al. (23) with modifications as described previously (8) . Briefly, serum samples were diluted 1 : 3 with phosphate buffer (pH 7.4) and subsequently 1 : 2 with sample buffer [62.5 mmol/l Tris-HCl (pH 6.8), 2% (w/v) sodium dodecyl sulphate (SDS), 10% (w/v) sucrose], boiled (5 min) and electrophoresed on a 5% stacking/12% separating SDS-polyacrylamide gel using the Mini Protean II system (BioRad, Munich, Germany). Separated proteins were transferred to a nitrocellulose membrane (Biorad). The blots were blocked in 1% fish gelatin and incubated with [
125 I]IGF-II (10 6 c.p.m. per blot). Membranes were washed and exposed to PhosphoImager screens that were scanned using a Storm 860 PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). The relative intensity of bands was calculated using the ImageQuantNT software package. In addition, IGFBPs were visualized by autoradiography (X-OMAT 228 film; Eastman Kodak Company, Rochester, NY, USA) for 48 h.
Statistical analysis
Analysis of variance [GLM procedure (24) ] was performed to estimate the effects of the presence or absence of the PEPCK-bGH (B) and PEPCK-IGF-II (I) transgenes respectively, of diet (standard diet compared with protein diet), and interactions between these factors. Means and standard errors were calculated and means were compared using Tukey tests (groups within diet) and Student's t-tests (diets within groups).
Results
Molecular size of serum IGF-II in PEPCK-IGF-II transgenic mice
Size fractionation of serum IGF-II at acidic pH (2.1) showed that PEPCK-IGF-II transgenic mice secrete predominantly 7.5 kDa human IGF-II, consistent with it being the fully processed mature polypeptide (Fig. 1 ).
Serum concentrations of GH and IGFs-I and -II
Mean serum GH concentrations in both B and IB mice corresponded to 900 ng/ml and increased more than twofold (P < 0:001) after 1 week of the protein diet ( Fig. 2A) . GH concentrations in controls and I mice were less than 20 ng/ml. Serum IGF-II concentrations of I and IB mice were three-to fourfold higher than those in C and B mice (P < 0:001; Fig. 2B ). Whereas IGF-II concentrations were not changed by the protein diet in the last two groups, IGF-II concentrations increased significantly in I (P < 0:001) and IB mice (P < 0:05). This increase was significantly (P < 0:05) less pronounced in IB than in I mice.
Circulating IGF-I concentrations were twofold (P < 0:001) higher in groups carrying (B, IB) than in those not carrying (C, I) the bGH transgene (Fig. 2C) . IGF-I concentrations tended to be lower in I than in C EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137 Figure 1 Size fractionation of IGF-II at acidic pH (2.1) in pooled serum from male PEPCK-IGF-II transgenic mice, taken after the high-protein, low-carbohydrate diet, indicating the presence of mature (7.5 kDa) peptide. Molecular weight markers are dextran blue (2000 kDa), ovalbumin (45 kDa), ribonuclease A (13.7 kDa), aprotinin (6.5 kDa) and sodium azide (0.07 kDa).
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and in IB than in B mice when the animals were maintained on the standard diet. The high-protein diet did not significantly change circulating IGF-I concentrations in controls and B mice, but resulted in a significant reduction of serum IGF-I concentrations in I (P < 0:05) and IB mice (P < 0:001) compared with the standard diet. Consequently, after PEPCK-IGF-II transgene expression was stimulated, serum IGF-I concentrations were significantly (P < 0:05) lower in I than in C and in IB than in B mice.
Serum concentrations of IGFBPs
Serum IGFBP-2 concentrations were determined by RIA and were significantly (P < 0:05) higher in I mice than in all other groups when animals were maintained on the standard diet (Fig. 3 ). There was a tendency to reduced IGFBP-2 concentrations in B mice. After the protein diet, serum IGFBP-2 concentrations did not change in C and I mice, but increased by two-to threefold in B and IB mice (P < 0:001).
Semi-quantitative evaluation of serum IGFBPs with apparent molecular weights of 39/43 kDa (IGFBP-3) and 23 kDa (presumably non-glycosylated IGFBP-4) was performed using ligand blot analysis (Fig. 4) . IGFBP-3 concentrations tended to be greater in groups carrying (B, IB) than in those not carrying the PEPCKbGH transgene (C, I); however, the values were variable and did not show significant differences between the groups except for significantly (P < 0:05) greater IGFBP-3 concentrations in IB than in I mice when C; A) . A first blood sample was taken from 12-week-old mice maintained on a standard rodent diet. A second blood sample was taken from the same animals 2 weeks later, after the mice had received a high-protein, low-carbohydrate diet for 1 week. Assays were performed as described in Materials and methods. The numbers of animals investigated in the various groups were: C: 10 males, 13 females; I: 12 males, 14 females; B: 10 males, 8 females; IB: 13 males, 14 females. Data presented are means and standard errors. Significant differences (P < 0:05) between groups within diet are indicated by differing superscripts (a, b, c and d). Within groups, differences between diets are marked by asterisks: *P < 0:05; ***P < 0:001.
Figure 3
Effects of diet and overproduction of GH, IGF-II, or both, on serum IGFBP-2 concentrations in transgenic mice expressing the PEPCK-IGF-II (I; left-downward-sloping cross-hatched bars), the PEPCK-bGH (B; right-downward-sloping cross-hatched bars) or both transgenes (IB; diamond cross-hatching), compared with non-transgenic littermates (C; A). Assay procedure, sampling scheme and numbers of animals investigated are described in Materials and methods and in the legend to Fig. 2 . The figure presents means and standard errors. Significant differences (P < 0:05) between groups within diet are indicated by differing superscripts (a, b, c and d). Within groups, differences between diets are marked by asterisks: ***P < 0:001. they were maintained on the standard diet. IGFBP-4 concentrations were significantly (P < 0:001) higher in B and IB than in C and I mice. The protein diet reduced serum IGFBP-4 in all groups, but this decrease reached a level of statistical significance only in the B (P < 0:01) and IB groups (P < 0:05).
Serum concentrations of insulin
Insulin concentrations were determined in serum samples from mice having food available ad libitum. When the mice were maintained on the standard diet, circulating insulin concentrations in B and IB mice exceeded those in C and I mice by several-fold (P < 0:001). The high-protein, low-carbohydrate diet did not change serum insulin concentrations of C and I mice, but resulted in a significant (P < 0:01) reduction of insulin concentrations in B mice. In IB mice, there was only a tendency to reduced insulin concentrations after the high-protein, low-carbohydrate diet (Fig. 5) .
Discussion
The effects and interactions of IGFs-I and -II and GH in vivo are only partially known. On the basis of the observation that co-infusion of IGF-II with IGF-I blocked the anti-catabolic effect of IGF-I in sheep (25) , it has been speculated that IGF-II may be a functional inhibitor of IGF-I, representing a mechanism that prevents overgrowth and hyperanabolism (6) . Another feature compatible with this hypothesis is the consistently observed decrease in serum IGF-I after administration of IGF-II to pituitary-sufficient animals (14) and in patients (26) or experimental animals (15) 
Interactions of IGF-II and GH in transgenic mice
705
Figure 4
Ligand blot analysis of serum samples from mice expressing the PEPCK-IGF-II (I; left-downward-sloping crosshatched bars), the PEPCK-bGH (B; right-downward-sloping crosshatched bars) or both transgenes (IB; diamond cross-hatching), compared with non-transgenic littermates (C; A) that were maintained on a standard rodent diet or a high-protein, low-carbohydrate diet. Ligand blot analysis was performed as described in Materials and methods using [ Data are presented as means and standard errors. Significant differences (P < 0:05) between groups within diet are indicated by differing superscripts (a, b and c). Differences within group between diets are marked by asterisks: *P < 0:05; **P < 0:01.
Figure 5
Serum insulin concentrations in mice expressing the PEPCK-IGF-II (I; left-downward-sloping cross-hatched bars; n ¼ 10), the PEPCK-bGH (B; right-downward-sloping crosshatched bars ; n ¼ 6) or both transgenes (IB; diamond crosshatching ; n ¼ 6), compared with non-transgenic littermates (C; A; n ¼ 10) maintained on a standard rodent diet or a high-protein, lowcarbohydrate diet. Data are presented as means and standard errors. Significant differences (P < 0:05) between groups within diet are indicated by differing superscripts (a and b). Differences within group between diets are marked by asterisks: **P < 0:01.
to suppress GH release and thus to reduce GH-dependent IGF-I production (15) . Alternatively, increased serum concentrations of either IGF-I or IGF-II may displace the other IGF from serum IGFBPs, leading to an accelerated plasma clearance rate (25) . To evaluate the roles of these potential mechanisms in vivo, we studied the regulation of serum concentrations of IGF-I and IGFBPs in transgenic mice characterized by overproduction of IGF-II, GH, or both. Measurements were made before and after stimulation of PEPCK promoter-controlled transgene expression by feeding a high-protein, low-carbohydrate diet.
As was expected from other studies that have used the PEPCK promoter (16) , serum concentrations of GH in B and IB mice, and circulating IGF-II concentrations in I and IB mice increased significantly after the highprotein diet, demonstrating correct nutritional regulation of both transgenes. Serum concentrations of GH were almost identical in B and IB mice, suggesting that an increased production of IGF-II did not affect basal and diet-stimulated PEPCK-bGH transgene expression.
In contrast, circulating IGF-II concentrations were affected by high concentrations of GH and IGF-I. Although serum IGF-II concentrations in I and IB mice maintained on the standard diet were almost identical, the increase in serum IGF-II concentrations after the high-protein diet was significantly smaller in IB than in I mice. This is in agreement with observations in lactating women, in whom the increase in serum IGF-I observed after GH administration was associated with a decrease in serum IGF-II (27) and may have been due to competition of IGFs-I and -II for the limited serum IGF-binding capacity and rapid clearance of free IGFs (28) .
The same mechanism may explain our findings regarding serum IGF-I concentrations in the transgenic mice. When the animals received the standard diet, serum IGF-I concentrations tended to be smaller in I than in C mice and in IB than in B mice. However, after high-protein diet-induced stimulation of PEPCK-IGF-II transgene expression, IGF-I concentrations decreased significantly in I and in IB mice, resulting in significantly lower serum IGF-I concentrations in I than in C mice and in IB than in B mice. As these changes occurred in the presence of high concentrations of GH, the observed reduction in IGF-I after stimulation of IGF-II expression is unlikely to have been a consequence of a GH-dependent mechanism but, rather, consequent upon the limited serum IGFBP pool and the short halflife of free IGFs. Measured concentrations of IGFs are known to represent almost exclusively IGFBP-bound IGFs (28) .
In addition to the relationship between serum IGFs-I and -II, we investigated effects of GH and IGFs on serum IGFBPs -a complex array of interactions that is just beginning to be understood. Consistent with our previous findings (8) and findings by other investigators (7), IGF-II overproduction increased the concentration of circulating IGFBP-2, suggesting that IGF-II is a regulator of IGFBP-2 expression. The effect of GH overexpression on serum IGFBP-2 concentrations was strongly influenced by diet. When the animals received a standard rodent diet, GH overproduction reduced serum IGFBP-2 both in the presence and in the absence of the PEPCK-IGF-II transgene. This observation complements findings from an experiment in which IGF-I transgenic mice were crossed with GH-deficient dwarf mice in which somatotrophs were genetically ablated by somatotroph-specific expression of a diphtheria toxin (29) . This study revealed greater serum IGFBP-2 concentrations in IGF-I-expressing, GH-deficient mice than in normal controls, suggesting an inhibitory effect of GH on IGFBP-2 secretion. In rats, hypophysectomy resulted in an increase in hepatic IGFBP-2 mRNA, which was, however, not re-suppressed by GH treatment, leading to the conclusion that other pituitary-dependent factors are responsible for the zero expression of IGFBP-2 in normal adult rats (30) . In the human circulation, IGFBP-2, measured by RIA, varies inversely with GH (21) and high concentrations of serum IGFBP-2 in patients suffering from non-islet cell tumour hypoglycaemia decreased after GH treatment (31), reflecting inverse GH-dependence of IGFBP-2. A role of insulin as regulator of IGFBP-2 secretion has been demonstrated both in vivo (32) and in vitro (33) . Markedly increased insulin concentrations in B and IB mice maintained on the standard diet could explain the reduced serum IGFBP-2 in these groups compared with that in C and I mice respectively.
A completely different effect of increased GH on serum IGFBP-2 concentrations was seen in B and IB mice when the animals received a diet with high protein and low carbohydrate content. Under these conditions, circulating IGFBP-2 increased two-to threefold. As the change of diet did not affect IGFBP-2 concentrations in controls and I mice, the markedly increased concentrations of IGFBP-2 in the GH transgenic groups seem to result from an interaction of GH and the high-protein, low-carbohydrate content of the diet, which -to our knowledge -has not been observed before and merits further investigation. Interestingly, this effect on IGFBP-2 concentrations was reversible, as IGFBP-2 concentrations decreased to the previous values after the standard diet was re-fed (data not shown). In B mice, the significant reduction in insulin concentrations after the protein diet may have been involved in the increase in serum IGFBP-2 concentrations. However, the increase in circulating IGFBP-2 was even more pronounced in IB mice, which showed only a tendency to reduced insulin concentrations when maintained on the protein diet, suggesting that additional factors are involved in the regulation of serum IGFBP-2.
Serum IGFBP-3 tended to be increased in B and IB mice, but the concentrations were variable and the differences mostly not statistically significant. Similarly, a considerable overlap of circulating IGFBP-3 concentrations has been observed between acromegalic patients and healthy subjects (34) , although IGFBP-3 is considered a sensitive marker of somatotroph function (35, 36) . For ovine metallothionein 1a-ovine GH transgenic mice, an increase in serum IGFBP-3 and hepatic IGFBP-3 mRNA expression has been reported as a consequence of heavy metal-induced GH overproduction (37) . In the present study, the increase in IGFBP-3, which represents the major pool for IGFs in the circulation (for review, see Ref. 13) , was relatively small compared with that in concentrations of IGF-I or IGFs-I and -II in B or IB mice respectively. This could explain the inverse relationship between serum IGFs-I and -II as a consequence of the limited serum IGF binding capacity.
The activity of IGFBP-4 was significantly increased in serum samples from GH-oversecreting mice, with no effect of simultaneous overproduction of IGF-II. Similarly, the concentration of IGFBP-4 in serum of rats doubled after treatment with bGH (38) . As IGFBP-4 is known to inhibit actions of IGFs (for review, see Ref. 13 ), up-regulation of this IGFBP in response to increased concentrations of GH could represent a mechanism that antagonizes the effects of concomitantly increased IGF-I.
In summary, our study has shown an inverse relationship of IGF-I and IGF-II in the presence of increased GH concentrations, suggesting that the reduction in circulating IGF-I concentrations by increased IGF-II is most probably the result of the limited serum IGF binding capacity, rather than of a reduction in GH-dependent IGF-I production. Effects of GH overproduction on serum IGFBP-2 concentrations depend on dietary factors and may be both inhibitory and stimulatory.
